Sjögren's syndrome (SjS)-like disease of mice: The importance of B lymphocytes and autoantibodies

Frontiers in Bioscience

Volumn 12, Issue 5, 2007, Pages 1767-1789

  Nguyen, Cuong Quoc ^a   Cha, Seunghee Ro ^a   Peck, Ammon Broughton ^a,b,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Autoantibodies; Autoimmune exocrinopathy; B lymphocytes; Mouse models; NOD mice; Review; Sj gren's syndrome

Indexed keywords

MUS;

EID: 34249816479     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2187     Document Type: Article

References (217)

1. R. I. Fox, and H. I. Kang: Pathogenesis of Sjogren's syndrome. Rheum Dis Clin North Am 18, 517-538. (1992)
2. P. C. Fox, and P. M. Speight: Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjogren's syndrome. Crit Rev Oral Biol Med 7, 144-158 (1996)
3. R. Jonsson, H. J. Haga, and T. P. Gordon: Current concepts on diagnosis, autoantibodies and therapy in Sjogren's syndrome. Scand J Rheumatol 29, 341-348. (2000)
4. R. Jonsson, S. J. Dowman, and T. Gordon: Sjögren's syndrome, in Arthritis and Allied Conditions-A Textbook in Rheumatology, W. Koopman, ed. Philadelphia Lippincott Williams & Wilkins, 2004, pp. 1681-1705.
5. N. Delaleu, R. Jonsson, and M. M. Koller: Sjogren's syndrome. Eur J Oral Sci 113, 101-113 (2005)
6. A. Hansen, P. E. Lipsky, and T. Dorner: New concepts in the pathogenesis of Sjogren syndrome: many questions, fewer answers. Curr Opin Rheumatol 15, 563-570. (2003)
7. R. Manthorpe, A. Bredberg, G. Henriksson, and A. Larsson: Progress and regression within primary Sjogren's syndrome. Scand J Rheumatol 35, 1-6 (2006)
8. L. Dawson, A. Tobin, P. Smith, and T. Gordon: Antimuscarinic antibodies in Sjogren's syndrome: where are we, and where are we going? Arthritis Rheum 52, 2984-2995 (2005)
9. A. Hansen, P. E. Lipsky, and T. Dorner: Immunopathogenesis of primary Sjogren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 17, 558-565 (2005)
10. T. P. Gordon, A. I. Bolstad, M. Rischmueller, R. Jonsson, and S. A. Waterman: Autoantibodies in primary Sjogren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 34, 123-132 (2001)
11. R. I. Fox, and P. Michelson: Approaches to the treatment of Sjogren's syndrome. J Rheumatol Suppl 61, 15-21. (2000)
12. D. A. Sullivan: Sex hormones and Sjogren's syndrome. J Rheumatol 24, 17-32. (1997)
13. D. A. Sullivan: Androgen deficiency & dry eye syndromes, Arch Soc Esp Oftalmol 79, 49-50 (2004)
14. I. Toda, L. A. Wickham, and D. A. Sullivan: Gender and androgen treatment influence the expression of protooncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice. Clin Immunol Immunopathol 86, 59-71 (1998)
15. D. W. Warren, A. M. Azzarolo, Z. M. Huang, B. W. Platler, R. L. Kaswan, E. Gentschein, F. L. Stanczyk, L. Becker, and A. K. Mircheff: Androgen support of lacrimal gland function in the female rabbit. Adv Exp Med Biol 438, 89-93 (1998)
16. L. A. Wickham, E. M. Rocha, J. Gao, K. L. Krenzer, L. A. da Silveira, I. Toda, and D. A. Sullivan: Identification and hormonal control of sex steroid receptors in the eye. Adv Exp Med Biol 438, 95-100 (1998)
17. C. Vitali, S. Bombardieri, R. Jonsson, H. M. Moutsopoulos, E. L. Alexander, S. E. Carsons, T. E. Daniels, P. C. Fox, R. I. Fox, S. S. Kassan, S. R. Pillemer, N. Talal, and M. H. Weisman: Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61, 554-558. (2002)
18. M. Dogru, M. E. Stern, J. A. Smith, G. N. Foulks, M. A. Lemp, and K. Tsubota: Changing trends in the definition and diagnosis of dry eyes. Am J Ophthalmol 140, 507-508 (2005)
19. D. Boumba, F. N. Skopouli, and H. M. Moutsopoulos: Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren's syndrome. Br J Rheumatol, 34, 326-333. (1995)
20. R. I. Fox, H. I. Kang, D. Ando, J. Abrams, and E. Pisa: Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 152, 5532-5539. (1994)
21. Y. Ohyama, S. Nakamura, G. Matsuzaki, M. Shinohara, A. Hiroki, T. Fujimura, A. Yamada, K. Itoh, and K. Nomoto: Cytokine messenger RNA expression in the labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 39, 1376-1384, (1996)
22. S. Yamano, J. C. Atkinson, B. J. Baum, and P. C. Fox: Salivary gland cytokine expression in NOD and normal BALB/c mice. Clin Immunol 92, 265-275. (1999)
23. M. Bachmann, S. Chang, H. Slor, J. Kukulies, and W. E. Muller: Shuttling of the autoantigen La between nucleus and cell surface after uv irradiation of human keratinocytes. Exp Cell Res 191, 171-180. (1990)
24. R. G. Beer, M. Rischmueller, T. Coates, A. W. Purcell, C. L. Keech, J. McCluskey, and T. P. Gordon: Nonprecipitating anti-La(SS-B) autoantibodies in primary Sjogren's syndrome. Clin Immunol Immunopathol 79, 314-318. (1996)
25. P. Caramaschi, D. Biasi, T. Manzo, A. Carletto, F. Poli, and L. M. Bambara: Anticentromere antibody-clinical associations. A study of 44 patients. Rheumatol Int 14, 253-255. (1995)
26. E. Feist, U. Kuckelkorn, T. Dorner, H. Donitz, S. Scheffler, F. Hiepe, P. M. Kloetzel, and G. R. Burmester: Autoantibodies in primary Sjogren's syndrome are directed against proteasomal subunits of the alpha and beta type. Arthritis Rheum 42, 697-702. (1999)
27. F. Folli, L. Perego, M. Ponzoni, A. M. Girardi, E. Bosi, A. J. Ferreri, M. Bellone, M. G. Sabbadini, A. M. Vicari, and L. Trusolino: Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjogren's syndrome and gastric MALT lymphoma. Ann Hematol 81, 597-602. (2002)
28. K. Fujii, W. Fujimoto, M. Ueda, E. Makino, and J. Arata: Detection of anti-type VII collagen antibody in Sjogren's syndrome/lupus erythematosus overlap syndrome with transient bullous systemic lupus erythematosus. Br J Dermatol 139, 302-306. (1998)
29. N. Haneji, T. Nakamura, K. Takio, K. Yanagi, H. Higashiyama, I. Saito, S. Noji, H. Sugino, and Y. Hayashi: Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome. Science 276, 604-607. (1997)
30. J. A. Hardin, and T. Mimori: Autoantibodies to ribonucleoproteins. Clin Rheum Dis 11, 485-505. (1985)
31. J. Kino-Ohsaki, I. Nishimori, M. Morita, K. Okazaki, Y. Yamamoto, S. Onishi, and M. A. Hollingsworth: Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjogren's syndrome. Gastroenterology 110, 1579-1586 (1996)
32. S. Muller, J. P. Briand, S. Barakat, J. Lagueux, G. G. Poirier, G. De Murcia, and D. A. Isenberg: Autoantibodies reacting with poly(ADP-ribose) and with a zinc-finger functional domain of poly(ADP-ribose) polymerase involved in the recognition of damaged DNA. Clin Immunol Immunopathol 73, 187-196. (1994)
33. E. M. Tan: Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44, 93-151(1989)
34. D. Cavill, S. A. Waterman, and T. P. Gordon: Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren's syndrome. Scand J Immunol 59, 261-266. (2004)
35. S. Cha, E. Singson, J. Cornelius, J. P. Yagna, H. J. Knot, and A. B. Peck: Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjogren's syndrome-associated autoantibodies. J Rheumatol. 33, 296-306. (2006)
36. J. Li, Y. M. Ha, N. Y. Ku, S. Y. Choi, S. J. Lee, S. B. Oh, J. S. Kim, J. H. Lee, E. B. Lee, Y. W. Song, and K. Park: Inhibitory effects of autoantibodies on the muscarinic receptors in Sjogren's syndrome. Lab Invest 27, 27 (2004)
37. S. A. Waterman, T. P. Gordon, and M. Rischmueller: Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum 43, 1647-1654. (2000)
38. L. J. Dawson, H. E. Allison, J. Stanbury, D. Fitzgerald, and P. M. Smith: Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches. Rheumatology (Oxford) 43, 1488-1495. Epub 2004 Sep 1487. (2004)
39. L. J. Dawson, E. A. Field, A. R. Harmer, and P. M. Smith: Acetylcholine-evoked calcium mobilization and ion channel activation in human labial gland acinar cells from patients with primary Sjogren's syndrome. Clin Exp Immunol 124, 480-485. (2001)
40. A. J. Smith, M. W. Jackson, F. Wang, D. Cavill, M. Rischmueller, and T. P. Gordon: Neutralization of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjogren syndrome. Hum Immunol 66, 411-416 (2005)
41. F. Wang, M. W. Jackson, V. Maughan, D. Cavill, A. J. Smith, S. A. Waterman, and T. P. Gordon: Passive transfer of Sjogren's syndrome IgG produces the pathophysiology of overactive bladder. Arthritis Rheum 50, 3637-3645. (2004)
42. J. Gao, S. Cha, R. Jonsson, J. Opalko, and A. B. Peck: Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren's syndrome patients by use of a transfected cell line assay. Arthritis Rheum 50, 2615-2621. (2004)
43. A. I. Bolstad, and R. Jonsson: Genetic aspects of Sjogren's syndrome. Arthritis Res 4, 353-359 (2002)
44. H. M. Fei, H. Kang, S. Scharf, H. Erlich, C. Peebles, and R. Fox. Specific HLA-DQA and HLA-DRB1 alleles confer susceptibility to Sjogren's syndrome. J Clin Lab Med 5, 382-391 (1991)
45. B. Nakken, R. Jonsson, K. A. Brokstad, K. Omholt, A. H. Nerland, H. J. Haga, and A. K. Halse: Associations of MHC class II alleles in Norwegian primary Sjogren's syndrome patients: implications for development of autoantibodies to the Ro52 autoantigen. Scand J Immunol 54, 428-433 (2001)
46. J. M. Anaya, R. D. Mantilla, and P. A. Correa: Immunogenetics of primary Sjogren's syndrome in Colombians. Semin Arthritis Rheum 34, 735-743 (2005)
47. C. P. Robinson, S. Yamachika, D. I. Bounous, J. Brayer, R. Jonsson, R. Holmdahl, A. B. Peck, and M. G. Humphreys-Beher: A novel NOD-derived murine model of primary Sjogren's syndrome. Arthritis Rheum 41, 150-156. (1998)
48. J. Brayer, J. Lowry, S. Cha, C. P. Robinson, S. Yamachika, A. B. Peck, and M. G. Humphreys-Beher: Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjogren's syndrome-like autoimmune exocrinopathy. J Rheumatol 27, 1896-1904. (2000)
49. S. Cha, H. Nagashima, V. B. Brown, A. B. Peck, and M. G. Humphreys-Beher: Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren's syndrome) on a healthy murine background. Arthritis Rheum 46, 1390-1398. (2002)
50. M. Voulgarelis, and H. M. Moutsopoulos: Lymphoproliferation in autoimmunity and Sjogren's syndrome. Curr Rheumatol Rep 5, 317-323 (2003)
51. A. Ambrosetti, R. Zanotti, C. Pattaro, L. Lenzi, M. Chilosi, P. Caramaschi, L. Arcaini, F. Pasini, D. Biasi, E. Orlandi, M. D'Adda, M. Lucioni, G. Pizzolo, M. Ramos-Casals, O. Trejo, M. Garcia-Carrasco, R. Cervera, G. De La Red, V. Gil, A. Lopez-Guillermo, M. Ingelmo, and J. Font: Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. Br J Haematol 126, 43-49. (2004)
52. M. Ramos-Casals, O. Trejo, M. Garcia-Carrasco, R. Cervera, G. De La Red, V. Gil, A. Lopez-Guillermo, M. Ingelmo, and J. Font: Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol 31, 495-499. (2004)
53. S. De Vita, M. Boiocchi, D. Sorrentino, A. Carbone, C. Avellini, R. Dolcetti, A. Marzotto, A. Gloghini, E. Bartoli, C. A. Beltrami, and G. Ferraccioli: Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome. Arthritis Rheum 40, 318-331. (1997)
54. J. B. Brayer, S. Cha, H. Nagashima, U. Yasunari, A. Lindberg, S. Diggs, J. Martinez, J. Goa, M. G. Humphreys-Beher, and A. B. Peck: IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjogren's syndrome. Scand J Immunol 54, 133-140. (2001)
55. S. Cha, J. Brayer, J. Gao, V. Brown, K. S, Y. U, and P. AB: A dual role for IFN-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the NOD mouse. Scand J Immunol In press, (2004)
56. J. Gao, S. Killedar, J. G. Cornelius, C. Nguyen, S. Cha, and A. B. Peck: Sjogren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotypespecific autoimmune disease. J Autoimmun. 26, 90-103. Epub 2006 Jan 2018. (2006)
57. C. P. Robinson, H. Yamamoto, A. B. Peck, and M. G. Humphreys-Beher: Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 79, 50-59. (1996)
58. J. B. Brayer, M. G. Humphreys-Beher, and A. B. Peck: Sjogren's syndrome: immunological response underlying the disease. Arch Immunol Ther Exp 49, 353-360 (2001)
59. S. Cha, A. B. Peck, and M. G. Humphreys-Beher: Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update. Crit Rev Oral Biol Med 13, 5-16 (2002)
60. S. Cha, S. C. van Blockland, M. A. Versnel, F. Homo-Delarche, H. Nagashima, J. Brayer, A. B. Peck, and M. G. Humphreys-Beher: Abnormal organogenesis in salivary gland development may initiate adult onset of autoimmune exocrinopathy. Exp Clin Immunogenet 18, 143-160 (2001)
61. C. P. Robinson, J. Cornelius, D. E. Bounous, H. Yamamoto, M. G. Humphreys-Beher, and A. B. Peck: Characterization of the changing lymphocyte populations and cytokine expression in the exocrine tissues of autoimmune NOD mice. Autoimmunity 27, 29-44 (1998)
62. C. P. Robinson, J. Cornelius, D. I. Bounous, H. Yamamoto, M. G. Humphreys-Beher, and A. B. Peck: Infiltrating lymphocyte populations and cytokine production in the salivary and lacrimal glands of autoimmune NOD mice. Adv Exp Med Biol 438, 493-497 (1998)
63. K. H. Nguyen, J. Brayer, S. Cha, S. Diggs, U. Yasunari, G. Hilal, A. B. Peck, and M. G. Humphreys-Beher: Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in nod mice. Arthritis Rheum 43, 2297-2306. (2000)
64. C. P. Robinson, J. Brayer, S. Yamachika, T. R. Esch, A. B. Peck, C. A. Stewart, E. Peen, R. Jonsson, and M. G. Humphreys-Beher: Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci U S A 95, 7538-7543. (1998)
65. R. H. Scofield, S. Asfa, D. Obeso, R. Jonsson, and B. T. Kurien: Immunization with short peptides from the 60-kDa Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjogren's syndrome. J Immunol 175, 8409-8414 (2005)
66. K. Takada, M. Takiguchi, A. Konno, and M. Inaba: Spontaneous development of multiple glandular and extraglandular lesions in aged IQI/Jic mice: a model for primary Sjogren's syndrome. Rheumatology (Oxford) 43, 858-862 (2004)
67. F. Mackay, S. A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, P. Schneider, J. Tschopp, and J. L. Browning: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190, 1697-1710 (1999)
68. J. Groom, S. L. Railed, A. H. Cutler, C. Olson, S. A. Woodcock, P. Schneider, J. Tschopp, T. G. Cachera, M. Batten, J. Wheway, D. Mauri, D. Cavill, T. P. Gordon, C. R. Mackay, and F. Mackay: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109, 59-68. (2002)
69. S, C. van Blokland, and M. A. Versnel: Pathogenesis of Sjogren's syndrome: characteristics of different mouse models for autoimmune exocrinopathy. Clin Immunol 103, 111-124 (2002)
70. K. Skarstein, A. H. Nerland, M. Eidsheim, J. D. Mountz, and R. Jonsson: Lymphoid cell accumulation in salivary glands of autoimmune MRL mice can be due to impaired apoptosis. Scand J Immunol 46, 373-378 (1997)
71. A. N. Theofilopoulos, and F. J. Dixon: Murine models of systemic lupus erythematosus. Adv Immunol 37, 269-390 (1985)
72. M. Wahren, K. Skarstein, I. Blange, I. Pettersson, and R. Jonsson: MRL/lpr mice produce anti-Ro 52,000 MW antibodies: detection, analysis of specificity and site of production. Immunology 83, 9-15 (1994)
73. R. Jonsson, A. Tarkowski, K. Backman, R. Holmdahl, and L. Klareskog: Sialadenitis in the MRL-1 mouse: morphological and immunohistochemical characterization of resident and infiltrating cells. Immunology 60, 611-616 (1987)
74. S. C. van Blokland, C. G. van Helden-Meeuwsen, A. F. Wierenga-Wolf, H. A. Drexhage, H. Hooijkaas, J. P. van de Merwe, and M. A. Versnel: Two different types of sialoadenitis in the NOD- and MRL/lpr mouse models for Sjogren's syndrome: a differential role for dendritic cells in the initiation of sialoadenitis? Lab Invest 80, 575-585. (2000)
75. J. B. Weinberg: Nitric oxide as an inflammatory mediator in autoimmune MRL-lpr/lpr mice. Environ Health Perspect 106 Suppl 5, 1131-1137 (1998)
76. Y. Hayashi, N. Haneji, and H. Hamano: Cytokine gene expression and autoantibody production in Sjogren's syndrome of MRL/lpr mice. Autoimmunity 23, 269-277 (1996)
77. R. W. Hoffman, M. A. Alspaugh, K. S. Waggie, J. B. Durham, and S. E. Walker: Sjogren's syndrome in MRL/1 and MRL/n mice. Arthritis Rheum 27,157-165. (1984)
78. K. Yanagi, N. Haneji, N. Ishimaru, I. Saito, and Y. Hayashi: Analysis of T cell receptor Vbeta usage in the autoimmune sialadenitis of non-obese diabetic (NOD) mice. Clin Exp Immunol 110, 440-446 (1997)
79. R. R. Hardy, and K. Hayakawa: B cell development pathways. Annu Rev Immunol 19, 595-621 (2001)
80. S. B. Gauld, J. M. Dal Porto, and J. C. Cambier: B cell antigen receptor signaling: roles in cell development and disease. Science 296, 1641-1642 (2002)
81. M. Busslinger: Transcriptional control of early B cell development. Annu Rev Immunol 22, 55-79 (2004)
82. M. D. Cooper: Exploring lymphocyte differentiation pathways. Immunol Rev 185, 175-185 (2002)
83. C. Segundo, C. Rodriguez, A. Garcia-Poley, M. Aguilar, I. Gavilan, C. Bellas, and J. A. Brieva: Thyroid-infiltrating B lymphocytes in Graves' disease are related to marginal zone and memory B cell compartments. Thyroid 11, 525-530 (2001)
84. N. F. Bernard, F. Ertug, and H. Margolese: High incidence of thyroiditis and anti-thyroid autoantibodies in NOD mice. Diabetes 41, 40-46 (1992)
85. S. Sugai, Y. Masaki, and L. Dong: Lymphoproliferative disorders in patients with Sjogren's syndrome. Autoimmun Rev 3 Suppl 1, S67-69(2004)
86. F. G. Kroese, W. A. Ammerlaan, and G. J. Deenen: Location and function of B-cell lineages. Ann N Y Acad Sci 651, 44-58 (1992)
87. R. Berland, and H. H. Wortis: Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 20, 253-300 (2002)
88. M. Viau, and M. Zouali: B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol 114, 17-26 (2005)
89. M. Haury, A. Sundblad, A. Grandien, C. Barreau, A. Coutinho, and A. Nobrega: The repertoire of serum IgM in normal mice is largely independent of external antigenic contact. Eur J Immunol 27, 1557-1563 (1997)
90. H. Masmoudi, T. Mota-Santos, F. Huetz, A. Coutinho, and P. A. Cazenave: All T15 Id-positive antibodies (but not the majority of VHT15+ antibodies) are produced by peritoneal CD5+ B lymphocytes. Int Immunol 2, 515-520 (1990)
91. K. Hayakawa, R. R. Hardy, M. Honda, L. A. Herzenberg, A. D. Steinberg, and L. A. Herzenberg: Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc Natl Acad Sci USA 81, 2494-2498 (1984)
92. S. D. Su, M. M. Ward, M. A. Apicella, and R. E. Ward: The primary B cell response to the O/core region of bacterial lipopolysaccharide is restricted to the Ly-1 lineage. J Immunol 146, 327-331 (1991)
93. F. G. Kroese, R. de Waard, and N. A. Bos: B-l cells and their reactivity with the murine intestinal microflora. Semin Immunol 8, 11-18 (1996)
94. M. Boes, A. P. Prodeus, T. Schmidt, M. C. Carroll, and J. Chen: A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 188, 2381-2386 (1998)
95. P. X. Shaw, S. Horkko, M. K. Chang, L. K. Curtiss, W. Palinski, G. J. Silverman, and J. L. Witztum: Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105, 1731-1740 (2000)
96. N. Baumgarth, J. Chen, O. C. Herman, G. C. Jager, and L. A. Herzenberg: The role of B-l and B-2 cells in immune protection from influenza virus infection. Curr Top Microbiol Immunol 252, 163-169 (2000)
97. J. M. Tuscano, G. S. Harris, and T. F. Tedder: B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications. Autoimmun Rev 2, 101-108 (2003)
98. F. Martin, and J. F. Kearney: Bl cells: similarities and differences with other B cell subsets, Curr Opin Immunol 13, 195-201 (2001)
99. M. Dauphinee, Z. Tovar, and N. Talal: B cells expressing CD5 are increased in Sjogren's syndrome. Arthritis Rheum 31, 642-647 (1988)
100. P. Youinou, L. Mackenzie, P. Katsikis, G. Merdrignac, D. A. Isenberg, N. Tuaillon, A. Lamour, P. Le Goff, J. Jouquan, A. Drogou, and et al.: The relationship between CDS-expressing B lymphocytes and serologic abnormalities in rheumatoid arthritis patients and their relatives. Arthritis Rheum 33, 339-348 (1990)
101. M. Zeher, P. Suranyi, G. Nagy, and G. Szegedi: B cells expressing CDS in minor labial salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 33, 453 (1990)
102. G. Bikah, J. Carey, J. R. Ciallella, A. Tarakhovsky, and S. Bondada: CDS-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 274, 1906-1909 (1996)
103. K. L. Hippen, L. E. Tze, and T. W. Behrens: CD5 maintains tolerance in anergic B cells. J Exp Med 191, 883-890 (2000)
104. R. E. Dolmetsch, R. S. Lewis, C. C. Goodnow, and J. I. Healy: Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature 386, 855-858 (1997)
105. R. Borland, and H. H. Wortis: Role of NFAT in the regulation of B-l cells. Curr Top Microbiol Immunol 252, 131-140 (2000)
106. S. Taki, M. Schmitt, D. Tarlinton, I. Forster, and K. Rajewsky: T cell-dependent antibody production by Ly-1 B cells. Ann N Y Acad Sci 651, 328-335 (1992)
107. S. Kaschner, A. Hansen, A. Jacobi, K. Reiter, N. L. Monson, M. Odendahl, G. R. Burmester, P. E. Lipsky, and T. Domer: Immunoglobulin Vlambda light chain gene usage in patients with Sjogren's syndrome. Arthritis Rheum 44, 2620-2632 (2001)
108. C. Heimbacher, A. Hansen, A. Pruss, A. Jacobi, K. Reiter, P. E. Lipsky, and T. Dorner: Immunoglobulin Vkappa light chain gene analysis in patients with Sjogren's syndrome. Arthritis Rheum 44, 626-637 (2001)
109. A. Hansen, M. Gosemann, A. Pruss, K. Reiter, S. Ruzickova, P. E. Lipsky, and T. Dorner: Abnormalities in peripheral B cell memory of patients with primary Sjogren's syndrome. Arthritis Rheum 50, 1897-1908. (2004)
110. H. Niiro, and E. A. Clark: Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2, 945-956 (2002)
111. J. C. Poe, M. Hasegawa, and T. F. Tedder: CD 19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction. Int Rev Immunol 20, 739-762. (2001)
112. C. A. Janeway, P. Travers, M. J. Walport, and M. Shlomchick: The immune system in health and disease, in Immunobiology, New York, NY Garland Publishing, 2001, pp. 221-293.
113. T. F. Tedder, M. Inaoki, and S. Sato: The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6, 107-118 (1997)
114. R. H. Carter, and D. T. Fearon: CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256, 105-107 (1992)
115. J. C. Poe, M. Fujimoto, P. J. Jansen, A. S. Miller, and T. F. Tedder: CD22 forms a quaternary complex with SHIP, Grb2, and Shc. A pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J Biol Chem 275, 17420-17427 (2000)
116. S. Sato, P. J. Jansen, and T. F. Tedder: CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Proc Natl Acad Sci USA 94, 13158-13162 (1997)
117. P. E. Lipsky: Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2, 764-766. (2001)
118. D. T. Fearon, and M. C. Carroll: Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 18, 393-422. (2000)
119. C. Nguyen, J. Cornelius, E. Singson, S. Killedar, S. Cha, and A. B. Peck: Role of complement and B lymphocytes in Sjogren's syndrome-like autoimmune exocrinopathy of NOD.B10-H2b mice. Mol Immunol 43, 1332-1339 (2006)
120. A. G. Baxter, and A. Cooke: Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice. Diabetes 42, 1574-1578. (1993)
121. M. C. Carroll: The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 16, 545-568. (1998)
122. J. G. Cyster, K. M. Ansel, K. Reif, E. H. Ekland, P. L. Hyman, H. L. Tang, S. A. Luther, and V. N. Ngo: Follicular stromal cells and lymphocyte homing to follicles. Immunol Rev 176, 181-193. (2000)
123. M. B. Fischer, S. Goerg, L. Shen, A. P. Prodeus, C. C. Goodnow, G. Kelsoe, and M. C. Carroll: Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 280, 582-585. (1998)
124. R. Molina, T. T. Provost, and E. L. Alexander: Two types of inflammatory vascular disease in Sjogren's syndrome. Differential association with seroreactivity to rheumatoid factor and antibodies to Ro (SS-A) and with hypocomplementemia. Arthritis Rheum 28, 1251-1258. (1985)
125. B. S. Thomsen, P. Oxholm, R. Manthorpe, and H. Nielsen: Complement C3b receptors on erythrocytes, circulating immune complexes, and complement C3 split products in patients with primary Sjogren's syndrome. Arthritis Rheum 29, 857-862. (1986)
126. M. Fischbach, D. Char, M. Christensen, T. Daniels, K. Whaley, M. Alspaugh, and N. Talal: Immune complexes in Sjogren's syndrome. Arthritis Rheum 23, 791-795. (1980)
127. H. Hacker, V. Redecke, B. Blagoev, I. Kratchmarova, L. C. Hsu, G. G. Wang, M. P. Kamps, E. Raz, H. Wagner, G. Hacker, M. Mann, and M. Karin: Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature. 439, 204-207. Epub 2005 Nov 2023. (2006)
128. C. Z. Ni, G. Oganesyan, K. Welsh, X. Zhu, J. C. Reed, A. C. Satterthwait, G. Cheng, and K. R. Ely: Key molecular contacts promote recognition of the BAFF receptor by TNF receptor-associated factor 3: implications for intracellular signaling regulation. J Immunol. 173, 7394-7400. (2004)
129. A. Hatzoglou, J. Roussel, M. F. Bourgeade, E. Rogier, C. Madry, J. Inoue, O. Devergne, and A. Tsapis: TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol. 165, 1322-1330. (2000)
130. H. Yamamoto, T. Kishimoto, and S. Minamoto: NF-kappaB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27. J Immunol. 161, 4753-4759. (1998)
131. J. Hauer, S. Puschner, P. Ramakrishnan, U. Simon, M. Bongers, C. Federle, and H. Engelmann: TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA. 102, 2874-2879. Epub 2005 Feb 2811. (2005)
132. P. Schneider: The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 17, 282-289. (2005)
133. F. Lavie, C. Miceli-Richard, J. Quillard, S. Roux, P. Leclere, and X. Mariette: Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 202, 496-502. (2004)
134. X. Mariette, S. Roux, J. Zhang, D. Bengoufa, F. Lavie, T. Zhou, and R. Kimberly: The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62, 168-171. (2003)
135. T. O. Hjelmervik, K. Petersen, I. Jonassen, R. Jonsson, and A. I. Bolstad: Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 52, 1534-1544. (2005)
136. A. Bobik, and N. Kalinina: Tumor necrosis factor receptor and ligand superfamily family members TNFRSF14 and LIGHT: new players in human atherogenesis. Arterioscler Thromb Vase Biol. 21, 1873-1875. (2001)
137. W. J. Kim, Y. J. Kang, E. M. Koh, K. S. Ahn, H. S. Cha, and W. H. Lee: LIGHT is involved in the pathogenesis of rheumatoid arthritis by inducing the expression of proinflammatory cytokines and MMP-9 in macrophages. Immunology. 114, 272-279. (2005)
138. M. Azuma, K. Aota, T. Tamatani, K. Motegi, T. Yamashita, Y. Ashida, Y. Hayashi, and M. Sato: Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjogren's syndrome patients. Arthritis Rheum 46, 1585-1594. (2002)
139. S. Yamachika, J. M. Nanni, K. H. Nguyen, L. Garces, J. M. Lowry, C. P. Robinson, J. Brayer, G. E. Oxford, A. da Silveira, M. Kerr, A. B. Peck, and M. G. Humphreys-Beher: Excessive synthesis of matrix metalloproteinases in exocrine tissues of NOD mouse models for Sjogren's syndrome. J Rheumatol 25, 2371-2380. (1998)
140. Y. Xiao, J. Hendriks, P. Langerak, H. Jacobs, and J. Borst: CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J Immunol 172, 7432-7441 (2004)
141. F. Mackay, P. Schneider, P. Rennert, and J. Browning: BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21, 231-264 (2003)
142. F. Mackay, and J. L. Browning: BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2, 465-475 (2002)
143. P. Schneider, F. MacKay, V. Steiner, K. Hofmann, J. L. Bodmer, N. Holler, C. Ambrose, P. Lawton, S. Bixler, H.
144. Acha-Orbea, D. Valmori, P. Romero, C. Werner-Favre, R. H. Zubler, J. L. Browning, and J. Tschopp: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189, 1747-1756 (1999)
145. L. G. Ng, C. R. Mackay, and F. Mackay: The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol 42, 763-772 (2005)
146. M. B. Litinskiy, B. Nardelli, D. M. Hilbert, B. He, A. Schaffer, P. Casali, and A. Cerutti: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3, 822-829 (2002)
147. B. Nardelli, O. Belvedere, V. Roschke, P. A. Moore, H. S. Olsen, T. S. Migone, S. Sosnovtseva, J. A. Carrell, P. Feng, J. G. Giri, and D. M. Hilbert: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97, 198-204 (2001)
148. H. B. Shu, W. H. Hu, and H. Johnson: TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 65, 680-683 (1999)
149. A. L. Gavin, D. Ait-Azzouzene, C. F. Ware, and D. Nemazee: DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 278, 38220-38228 (2003)
150. A. L. Gavin, B. Duong, P. Skog, D. Ait-Azzouzene, D. R. Greaves, M. L. Scott, and D. Nemazee: deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 175, 319-328 (2005)
151. G. M. Kolfschoten, B. Pradet-Balade, M. Hahne, and J. P. Medema: TWE-PRIL; a fusion protein of TWEAK and APRIL. Biochem Pharmacol 66, 1427-1432 (2003)
152. A. Tardivel, A. Tinel, S. Lens, Q. G. Steiner, E. Sauberli, A. Wilson, F. Mackay, A. G. Rolink, F. Beermann, J. Tschopp, and P. Schneider: The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur J Immunol 34, 509-518 (2004)
153. H. Hase, Y. Kanno, M. Kojima, K. Hasegawa, D. Sakurai, H. Kojima, N. Tsuchiya, K. Tokunaga, N. Masawa, M. Azuma, K. Okumura, and T. Kobata: BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 103, 2257-2265 (2004)
154. A. Patke, I. Mecklenbrauker, and A. Tarakhovsky: Survival signaling in resting B cells. Curr Opin Immunol 16, 251-255 (2004)
155. L. Gorelik, A. H. Cutler, G. Thill, S. D. Miklasz, D. E. Shea, C. Ambrose, S. A. Bixler, L. Su, M. L. Scott, and S. L. Kalled: Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 172, 762-766 (2004)
156. S. D. Khare, I. Sarosi, X. Z. Xia, S. McCabe, K. Miner, I. Solovyev, N. Hawkins, M. Kelley, D. Chang, G. Van, L. Ross, J. Delaney, L. Wang, D. Lacey, W. J. Boyle, and H. Hsu: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 97, 3370-3375 (2000)
157. T. Mimori: Autoantibodies in connective tissue diseases: clinical significance and analysis of target autoantigens. Intern Med 38, 523-532 (1999)
158. J. B. Harley, E. L. Alexander, W. B. Bias, O. F. Fox, T. T. Provost, M. Reichlin, H. Yamagata, and F. C. Arnett: Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjogreris syndrome. Arthritis Rheum 29, 196-206. (1986)
159. Y. Hayashi, R. Arakaki, and N. Ishimaru: Apoptosis and estrogen deficiency in primary Sjogren syndrome. Curr Opin Rheumatol 16, 522-526 (2004)
160. M. Kobayashi, N. Yasui, N. Ishimaru, R. Arakaki, and Y. Hayashi: Development of autoimmune arthritis with aging via bystander T cell activation in the mouse model of Sjogren's syndrome. Arthritis Rheum 50, 3974-3984 (2004)
161. K. Takada, M. Takiguchi, A. Konno, and M. Inaba: Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjogren's syndrome. J Biol Chem. 280, 3982-3988. Epub 2004 Nov 3915. (2005)
162. H. Katoh: Animal models derived from the ICR mouse for human diseases. Medical Immunology 17, 353-361 (in Japanese) (1989)
163. C. P. Robinson, D. I. Bounous, C. E. Alford, A. B. Peck, and M. G. Humphreys-Beher: Aberrant expression and potential function for parotid secretory protein (PSP) in the NOD (non-obese diabetic) mouse. Adv Exp Med Biol 438, 925-930 (1998)
164. S. Winer, I. Astsaturov, R. Cheung, H. Tsui, A. Song, R. Gaedigk, D. Winer, A. Sampson, C. McKerlie, A. Bookman, and H. M. Dosch: Primary Sjogren's syndrome and deficiency of ICA69. Lancet 360, 1063-1069 (2002)
165. A. Rosen, and L. Casciola-Rosen: Altered autoantigen structure in Sjogren's syndrome: implications for the pathogenesis of autoimmune tissue damage. Crit Rev Oral Biol Med 15, 156-164 (2004)
166. J. C. Hall, L. Casciola-Rosen, and A. Rosen: Altered structure of autoantigens during apoptosis. Rheum Dis Clin North Am 30, 455-471, vii (2004)
167. L. A. Casciola-Rosen, G. Anhalt, and A. Rosen: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179, 1317-1330. (1994)
168. L. A. Casciola-Rosen, G. J. Anhalt, and A. Rosen: DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J Exp Med 182, 1625-1634. (1995)
169. L. Casciola-Rosen, F. Andrade, D. Ulanet, W. B. Wong, and A. Rosen: Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 190, 815-826 (1999)
170. M. Ohlsson, P. Szodoray, L. L. Loro, A. C. Johannessen, and R. Jonsson: CD40, CD154, Bax and Bcl-2 expression in Sjogren's syndrome salivary glands: a putative anti-apoptotic role during its effector phases. Scand J Immunol 56, 561-571 (2002)
171. P. J. Utz, M. Hottelet, T. M. Le, S. J. Kim, M. E. Geiger, W. J. van Venrooij, and P. Anderson: The 72-kDa component of signal recognition particle is cleaved during apoptosis. J Biol Chem 273, 35362-35370 (1998)
172. H. A. Doyle, and M. J. Mamula: Posttranslational protein modifications: new flavors in the menu of autoantigens. Curr Opin Rheumatol 14, 244-249 (2002)
173. M. Sugai, H. Gonda, Y. Nambu, Y. Yokota, and A. Shimizu: Role of Id proteins in B lymphocyte activation: new insights from knockout mouse studies. J Mol Med 82, 592-599 (2004)
174. M. Kowanetz, U. Valcourt, R. Bergstrom, C. H. Heldin, and A. Moustakas: Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol 24, 4241-4254 (2004)
175. H. Li, M. Dai, and Y. Zhuang: A T cell intrinsic role of Id3 in a mouse model for primary Sjogren's syndrome. Immunity 21, 551-560 (2004)
176. S. Salomonsson, M. V. Jonsson, K. Skarstein, K. A. Brokstad, P. Hjelmstrom, M. Wahren-Herlenius, and R. Jonsson: Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 48, 3187-3201. (2003)
177. P. Szodoray, S. Jellestad, M. O. Teague, and R. Jonsson: Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjogren's syndrome. Lab Invest 83, 357-365. (2003)
178. P. Szodoray, S. Jellestad, P. Alex, T. Zhou, P. C. Wilson, M. Centola, J. G. Brun, and R. Jonsson: Programmed Cell Death of Peripheral Blood B Cells Determined by Laser Scanning Cytometry in Sjogren's Syndrome with a Special Emphasis on BAFF. J Clin Immunol 24, 600-611. (2004)
179. D. Cavill, S. A. Waterman, and T. P. Gordon: Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission. Arthritis Rheum 48, 3597-3602. (2003)
180. A. D. Keegan, J. A. Johnston, P. J. Tortolani, L. J. McReynolds, C. Kinzer, J. J. O'Shea, and W. E. Paul: Similarities and differences in signal transduction by interleukin 4 and interleukin 13: analysis of Janus kinase activation. Proc Natl Acad Sci USA 92, 7681-7685. (1995)
181. A. Nakajima, S. Hirose, H. Yagita, and K. Okumura: Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol 158, 1466-1472. (1997)
182. S. L. Peng, J. Moslehi, and J. Craft: Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 99, 1936-1946. (1997)
183. B. M. Ruger, K. J. Erb, Y. He, J. M. Lane, P. F. Davis, and Q. Hasan: Interleukin-4 transgenic mice develop glomerulosclerosis independent of immunoglobulin deposition. Eur J Immunol 30, 2698-2703. (2000)
184. R. R. Singh: IL-4 and many roads to lupuslike autoimmunity. Clin Immunol 108, 73-79. (2003)
185. B. Wang, A. Gonzalez, P. Hoglund, J. D. Katz, C. Benoist, and D. Mathis: Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes 47, 1207-1211. (1998)
186. N. Hill, and N. Sarvetnick: Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol 14, 791-797. (2002)
187. M. F. White: The IRS-1 signaling system. Curr Opin Genet Dev 4, 47-54. (1994)
188. A. D. Keegan, K. Nelms, L. M. Wang, J. H. Pierce, and W. E. Paul: Interleukin 4 receptor: signaling mechanisms. Immunol Today 15, 423-432. (1994)
189. B. Kyewski, and J. Derbinski: Self-representation in the thymus: an extended view. Nat Rev Immunol 4, 688-698. (2004)
190. D. Mathis, and C. Benoist: Back to central tolerance. Immunity 20, 509-516. (2004)
191. L. Hunziker, M. Recher, A. J. Macpherson, A. Ciurea, S. Freigang, H. Hengartner, and R. M. Zinkernagel: Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat Immunol 4, 343-349. (2003)
192. D. A. Yarilin, J. Valiando, and D. N. Posnett: A mouse herpesvirus induces relapse of experimental autoimmune arthritis by infection of the inflammatory target tissue. J Immunol 173, 5238-5246. (2004)
193. P. G. Isaacson, and M. Q. Du: MALT lymphoma: from morphology to molecules. Nat Rev Cancer 4, 644-653. (2004)
194. Y. Masaki, and S. Sugai: Lymphoproliferative disorders in Sjogren's syndrome. Autoimmun Rev 3, 175-182 (2004)
195. T. Suzuki, K. Matsuo, H. Ito, K. Hirose, K. Wakai, T. Saito, S. Sato, Y. Morishima, S. Nakamura, R. Ueda, and K. Tajima: A past history of gastric ulcers and Helicobacter pylori infection increase the risk of gastric malignant lymphoma. Carcinogenesis, (2006)
196. J. A. DiGiuseppe, R. L. Corio, and W. H. Westra: Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. Curr Opin Oncol 8, 232-237 (1996)
197. P. Caramaschi, D. Biasi, A. Carletto, A. Ambrosetti, S. Mocella, M. Randon, and L. M. Bambara: [MALT lymphomas of the salivary glands. Review of the literature apropos of a case in a patient with hepatitis C virus infection]. Recenti Prog Med 90, 585-591 (1999)
198. A. J. Novak, D. M. Grote, M. Stenson, S. C. Ziesmer, T. E. Witzig, T. M. Habermann, B. Harder, K. M. Ristow, R. J. Bram, D. F. Jelinek, J. A. Gross, and S. M. Ansell: Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104, 2247-2253 (2004)
199. C. Kern, J. F. Cornuel, C. Billard, R. Tang, D. Rouillard, V. Stenou, T. Defrance, F. Ajchenbaum-Cymbalista, P. Y. Simonin, S. Feldblum, and J. P. Kolb: Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103, 679-688 (2004)
200. J. Moreaux, E. Legouffe, E. Jourdan, P. Quittet, T. Reme, C. Lugagne, P. Moine, J. F. Rossi, B. Klein, and K. Tarte: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148-3157 (2004)
201. B. He, A. Chadburn, E. Jou, E. J. Schattner, D. M. Knowles, and A. Cerutti: Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 172, 3268-3279 (2004)
202. B. Klein, K. Tarte, M. Jourdan, K. Mathouk, J. Moreaux, E. Jourdan, E. Legouffe, J. De Vos, and J. F. Rossi: Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78, 106-113 (2003)
203. M. Batten, C. Fletcher, L. G. Ng, J. Groom, J. Wheway, Y. Laabi, X. Xin, P. Schneider, J. Tschopp, C. R. Mackay, and F. Mackay: TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 172, 812-822 (2004)
204. G. A. McCarty: Autoantibodies and their relation to rheumatic diseases. Med Clin North Am 70, 237-261. (1986)
205. S. Bacman, L. Sterin-Borda, J. J. Camusso, R. Arana, O. Hubscher, and E. Borda: Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren's syndrome. Clin Exp Immunol 104, 454-459. (1996)
206. H. Yamamoto, N. E. Sims, S. P. Macauley, K. H. Nguyen, Y. Nakagawa, and M. G. Humphreys-Beher: Alterations in the secretory response of non-obese diabetic (NOD) mice to muscarinic receptor stimulation. Clin Immunol Immunopathol 78, 245-255. (1996)
207. N. Pourmand, M. Wahren-Herlenius, I. Gunnarsson, E. Svenungsson, B. Lofstrom, Y. Ioannou, D. A. Isenberg, and C. G. Magnusson: Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjogren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 58, 623-629. (1999)
208. H. S. Kessler, M. Cubberly, and W. Manski: Eye changes in autoimmune NZB and NZB × NZW mice. Comparison with Sjogren's syndrome. Arch Ophthalmol 85, 211-219. (1971)
209. S. Makino, K. Kunimoto, Y. Muraoka, Y. Mizushima, K. Katagiri, and Y. Tochino: Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29, 1-13. (1980)
210. M. G. Humphreys-Beher, Y. Hu, Y. Nakagawa, P. L. Wang, and K. R. Purushotham: Utilization of the non-obese diabetic (NOD) mouse as an animal model for the study of secondary Sjogren's syndrome. Adv Exp Med Biol 350, 631-636 (1994)
211. T. Lund, L. O'Reilly, P. Hutchings, O. Kanagawa, E. Simpson, R. Gravely, P. Chandler, I. Dyson, J. K. Picard, A. Edwards, and et al.: Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain. Nature 345, 727-729. (1990)
212. A. K. Lindqvist, B. Nakken, M. Sundler, P. Kjellen, R. Jonsson, R. Holmdahl, and K. Skarstein: Influence on spontaneous tissue inflammation by the major histocompatibility complex region in the nonobese diabetic mouse. Scand J Immunol 61, 119-127 (2005)
213. L. D. Shultz, P. A. Schweitzer, S. W. Christianson, B. Gott, I. B. Schweitzer, B. Tennent, S. McKenna, L. Mobraaten, T. V. Rajan, D. L. Greiner, and et al.: Multiple defects in innate and adaptive immunologie function in NOD/LtSz-scid mice. J Immunol 154, 180-191. (1995)
214. N. Haneji, H. Hamano, K. Yanagi, and Y. Hayashi: A new animal model for primary Sjogren's syndrome in NFS/sld mutant mice. J Immunol 153, 2769-2777. (1994)
215. G. J. Shim, M. Warner, H. J. Kim, S. Andersson, L. Liu, J. Ekman, O. Imamov, M. E. Jones, E. R. Simpson, and J. A. Gustafsson: Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc Natl Acad Sci USA 101, 12628-12633. Epub 12004 Aug 12616. (2004)
216. R. Tsubata, T. Tsubata, H. Hiai, R. Shinkura, R. Matsumura, T. Sumida, S. Miyawaki, H. Ishida, S. Kumagai, K. Nakao, and T. Honjo: Autoimmune disease of exocrine organs in immunodeficient alymphoplasia mice: a spontaneous model for Sjogren's syndrome. Eur J Immunol 26, 2742-2748. (1996)
217. K. Fujiwara, N. Sakaguchi, and T. Watanabe: Sialoadenitis in experimental graft-versus-host disease. An animal model of Sjogren's syndrome. Lab Invest 65, 710-718. (1991)